Evidence guide · US
Nutrient gaps on Wegovy or Mounjaro: what four small diet studies found
A November 17, 2026 BMJ study of 14 patients at an English general practice who were prescribed GLP-1 medicines found an average intake of 1,231 kcal a day and common shortfalls in fiber, vitamin D and iron. Two other diet studies found similar vitamin and mineral gaps. An Italian app study found lower energy and protein, not those micronutrients. What it means for food, vitamins and supplements.
Review type: research summary. This page summarises published research and product labels, cited below.
GLP-1 medicines such as semaglutide (Wegovy, Ozempic) and tirzepatide (Mounjaro) cut appetite, and that is a large part of how they work. Eating much less for months raises a simple question: are people still getting enough fiber, vitamins and minerals? On November 17, 2026 BMJ Nutrition, Prevention & Health published a small study from an English general practice that looked at what 14 patients on these medicines actually ate. It joins three other small diet studies from the UK, Italy and the US.
Short answer: the gaps that were measured often match, but the four studies do not all say the same thing. In the two UK studies and the US study, many people were below reference intakes for fiber, vitamin D and iron. Magnesium and potassium were short in the Lobo and Johnson studies. Energy intake was low in the UK studies (1,231 and 1,337 kcal a day) and lower in Italian GLP-1 users than in non-users (1,102 v 1,281 kcal). The US study did not show a low-energy pattern: average intake was 1,748 kcal a day, which those authors described as above the calorie ranges they cited for people on these medicines. The Italian study reported energy and macronutrients only, not vitamins or minerals. Whether protein was short depends on how it was measured. The studies are small, rely on short self-reported records and did not measure blood levels or health outcomes, so they show a risk of shortfall, not proven deficiency. The practical message is to plan meals around nutrient-dense food, follow standard vitamin D advice and ask the prescriber about monitoring, rather than to buy a "GLP-1 support" product.
Grades used here: Strong (consistent results from several good-quality human trials), Moderate (good trials, but few or with mixed results), Limited (small or low-quality human studies, or good studies in other groups of people), Insufficient (too little human research to judge) and Evidence of harm.
The new UK study: 14 patients at one general practice
The authors, from the University of Oxford, the NNEdPro Global Institute for Food, Nutrition and Health, Ulster University and Brackley Medical Centre, describe the work as an exploratory service evaluation. Fourteen adults prescribed GLP-1 or dual GIP/GLP-1 medicines at one general practice in England (10 with private prescriptions and 4 through the NHS) recalled what they had eaten over the previous two days using the myfood24 online diary. Intakes of 28 nutrients were compared with UK reference nutrient intakes (RNIs), and the team looked closely at six: fiber, iron, vitamin D, potassium, protein and magnesium. A clinically relevant shortfall was defined as less than two-thirds of the RNI. Participants were also interviewed about their experience of treatment.
What it found
- Average energy intake was 1,231 kcal a day, 58.5% of estimated requirements. Three people ate under 800 kcal a day, and more than half ate less than two-thirds of their estimated need.
- More than three-quarters were below two-thirds of the RNI for both fiber and vitamin D, and half were below that threshold for iron.
- Eight of the 14 fell below two-thirds of the RNI for three or more of the six focus nutrients, and one fell short on all six. None of the 14 reached 400 g of fruit and vegetables a day.
- Protein was the exception: average intake was 153% of the RNI, and only one participant was below it.
- Ultra-processed food supplied 33% of energy on average, with a wide range; for one person it was 84%.
In interviews, participants linked eating less to appetite suppression. Many described little structured follow-up, side effects such as dizziness and low blood pressure that were not reviewed, and turning to online peer groups for advice. Two were shocked by how little they were eating once they filled in the diary. The authors note that UK dietary advice, the Eatwell Guide, was not designed for people on these medicines and that no drug-specific nutritional monitoring framework exists. They add that the high share of private prescriptions suggests nutritional safety netting may be thinner outside NHS pathways.
The limits are plain and the authors state them: 14 people, one practice in a relatively affluent area, two days of self-reported intake and no comparison group. It is observational, so it cannot show that the medicine caused the shortfalls, and the authors call the findings hypothesis-generating.
Three other diet studies point the same way
- A UK questionnaire study (Lobo, Institute for Optimum Nutrition), published as a conference abstract in September 2026: 38 adults on GLP-1 medicines, mean age 51.6, 86.8% women, kept three-day food diaries. Mean intake was 1,337 kcal a day and 89.5% were below their estimated average requirement (EAR) for energy. All were below the 30 g fiber target (mean 14.5 g). More than 90% were below the RNI for vitamin D, potassium and selenium, 81.6% for iron and 78.9% for magnesium, and 44.7% fell short of 0.75 g of protein per kg of body weight, which the abstract calls the estimated average requirement (EAR). Although 73.7% took supplements, fewer than 10% did so under professional guidance.
- An Italian app-based study presented at the European Congress on Obesity in May 2026 (Vinelli and colleagues, San Raffaele Hospital, Milan) compared 116 GLP-1 users with 216 non-users who logged meals in a dietary tracking app. Users ate less (1,102 v 1,281 kcal a day) and less protein (53.8 v 62.0 g a day), averaging 0.6 g per kg; 88% were below the Italian recommendation of 0.9 g per kg. They also skipped meals more often. The lead author is a scientific advisor to the company that makes the app, and the work was a congress abstract, not a peer-reviewed paper.
- A US cross-sectional study (Johnson and colleagues, 2025): 69 adults on GLP-1 medicines for at least a month kept three-day food records. Intakes of fiber (14.5 g), calcium, iron, magnesium, potassium, choline and vitamins A, C, D and E were below US Dietary Reference Intakes, while B vitamins, copper, phosphorus, selenium and zinc were adequate. Unlike the other studies, average energy intake was 1,748 kcal a day. Protein was within the usual share of calories but below the higher per-kilogram targets the authors used for weight loss. All authors were employed by, and the study was funded by, GNC Holdings, a supplement retailer.
Diet shortfalls on GLP-1 medicines: Limited (four small observational studies)
Fiber, vitamin D and iron came up short in the Ammineni (14), Lobo (38) and Johnson (69) studies. Magnesium and potassium were also short in the Lobo and Johnson studies. Vinelli's 332 adults were 116 GLP-1 users and 216 non-users, and that study reported energy and macronutrients only, not those vitamins and minerals. The repeated gaps are worth taking seriously. But every study relied on self-reported diaries or app logs over a few days, none measured blood levels, and none followed people long enough to see whether low intakes caused harm. Two had commercial links (an app maker and a supplement retailer). Protein depends on the yardstick. In Ammineni, average intake was 153% of the UK reference nutrient intake and one person was below it. In Lobo, 44.7% were below 0.75 g per kg, which the abstract calls the estimated average requirement rather than a weight-loss target. Johnson's group was within the usual share of calories from protein but often below the higher per-kilogram targets those authors used for weight loss. Vinelli's users averaged 0.6 g per kg, and 88% were below Italy's 0.9 g per kg recommendation.
What the joint Advisory says
A 2025 joint Advisory from the American College of Lifestyle Medicine, the American Society for Nutrition, the Obesity Medicine Association and The Obesity Society lists nutritional deficiencies due to calorie reduction among the main challenges of GLP-1 treatment, alongside gastrointestinal side effects and loss of muscle and bone. Its priorities during treatment include managing gastrointestinal side effects, preventing nutrient deficiencies and preserving muscle and bone through resistance training and appropriate diet, with support such as counseling from a registered dietitian.
Supplements to fill the gaps: Insufficient direct evidence
None of the four studies shows that a supplement changes health outcomes for people on GLP-1 medicines. Lobo wrote that supplement use partly covered some shortfalls, which describes intake, not a health benefit. A supplement can cover a specific, known gap, such as vitamin D in winter, but it does not replace the energy, protein and fiber that come with food, and a product sold for "GLP-1 support" has no special standing. The supplement use reported in the UK questionnaire study was mostly unsupervised.
Our view
- Where micronutrients were measured, many people ate too little fiber, vitamin D and iron, and the Lobo and Johnson studies also found magnesium and potassium short. The evidence is small and based on short self-reported records, so treat it as a reason to check, not proof of deficiency.
- Very low intakes matter most. Three of 14 people in the BMJ study ate under 800 kcal a day. If you are eating far less than before, tell your prescriber.
- Food first: build meals around protein foods, vegetables, fruit, beans, whole grains and dairy or fortified alternatives, eaten in small portions if appetite is low.
- If you use a supplement, choose it for a specific gap you know about, tell your prescriber or pharmacist, and do not take several overlapping products.
US rules
The FDA does not approve dietary supplements before they are marketed, and a product sold as a supplement but represented to treat, prevent or cure a disease meets the definition of a drug. A product marketed to treat obesity or diabetes, including one sold as a replacement for a GLP-1 medicine, is an example of that kind of claim. US Dietary Reference Intakes were the yardstick in the Johnson study, whose authors worked for a supplement retailer. Tell your prescriber or pharmacist before adding supplements, and report suspected side effects of the medicine to the FDA through MedWatch.
FAQ
Do GLP-1 medicines cause vitamin deficiencies?
These four studies show low intakes, not measured deficiencies. The three that recorded vitamins and minerals found many users below reference intakes for fiber, vitamin D and iron. Lobo and Johnson also found magnesium and potassium short. None of the four measured blood levels, and none showed that the medicine caused the shortfalls.
Which nutrients are most often low on Wegovy or Mounjaro?
Fiber and vitamin D came up short in the three studies that measured them. The Italian app study did not report vitamins or minerals. Iron was low in those three studies. Magnesium and potassium were low in the Lobo and Johnson studies. Protein depends on the yardstick: Ammineni's average was 153% of the UK reference intake, with one person below it, while 44.7% of Lobo's group were below 0.75 g per kg. Higher per-kilogram targets used for weight loss, and Italy's 0.9 g per kg recommendation, were often missed.
Should I take a multivitamin on a GLP-1 medicine?
These four studies do not show that a multivitamin improves outcomes for people on these medicines. Food comes first. A supplement can make sense for a known gap such as vitamin D, and your prescriber or pharmacist can tell you whether blood tests are worth doing.
How little is too little to eat?
These studies do not set a single cutoff for eating too little. In the BMJ study, average intake was 58.5% of estimated needs and three people ate under 800 kcal a day. If you are regularly eating very little, or you feel dizzy, speak to your prescriber.
Sources
These are the documents this page relies on.
- Ammineni D, Ottolini M, Ray S, Golubic R, Fallows E. Uncovering nutritional deficiencies and the adequacy of wrap-around care for patients on GLP-1 and dual GIP/GLP-1 receptor agonists. BMJ Nutr Prev Health. Published online November 17, 2026BMJ Nutrition, Prevention & Health (doi 10.1136/bmjnph-2026-001622)
- Lobo N. Nutritional assessment of diet quality and potential deficiencies in individuals using GLP-1 receptor agonist medications: a questionnaire study (abstract 32). Lifestyle Medicine Advances. 2026;1(Suppl 1):A1.2Lifestyle Medicine Advances (BMJ), conference abstract
- AI-based monitoring reveals protein deficiencies in people taking GLP-1 receptor agonists for weight loss (European Congress on Obesity 2026 abstract, Vinelli V and colleagues)European Association for the Study of Obesity, via EurekAlert (April 9, 2026)
- Johnson B, Milstead M, Thomas O, et al. Investigating nutrient intake during use of glucagon-like peptide-1 receptor agonist: a cross-sectional study. Front Nutr. 2025;12:1566498Frontiers in Nutrition (PubMed 40352260)
- Mozaffarian D, Agarwal M, Aggarwal M, et al. Nutritional priorities to support GLP-1 therapy for obesity: a joint Advisory from the American College of Lifestyle Medicine, the American Society for Nutrition, the Obesity Medicine Association, and The Obesity Society. Obesity. 2025Obesity (PubMed 40445127)
- Vitamin D: vitamins and mineralsNHS
- How to get more fiber into your dietNHS
- Questions and answers on dietary supplementsUS Food and Drug Administration
- MedWatch: the FDA safety information and adverse event reporting programUS Food and Drug Administration